NATRNasdaq

NATURES SUNSHINE PRODUCTS INC

Pharmaceutical Preparations · UT · CIK 275053

Manufactures and directly sells nutritional and personal care products through independent consultants

red 8-K · 90d

+ Watch View on EDGAR ↗

$361M

Market cap

$21.56

Last close

+2.6%

+5.7%

167K

Volume

Price · last 39 sessions-17.2%

May 4L $19.68 · H $26.23Jun 29

238

Total filings

May 11, 2026

Last filing

12/31

Fiscal year end

All 8-K · 128 10-Q · 46 DEF 14A · 17 10-K · 15 DEFA14A · 14 8-K/A · 6 11-K · 4 SC 13G · 3

Insider Activity

In the 90 days to Jun 12, 2026: 1 sold $41K.

Date	Insider	Action	Shares	Price	Value
Jun 12, 2026	Herbert Kevin R.EVP & President, North America	Sell	1,134	$20.63	$23K
Jun 12, 2026	Herbert Kevin R.EVP & President, North America	Sell	866	$20.75	$18K
Mar 13, 2026	Yates Bryant JEVP & President, Europe	Sell	19,516	$24.35	$475K
Mar 13, 2026	Norman Daniel CEVP & President, Asia	Sell	15,383	$24.52	$377K
Mar 13, 2026	Lanoy Jonathan DavidSVP, Chief Accounting Officer	Sell	4,000	$24.70	$99K
Dec 12, 2025	Yates Bryant JEVP & President, Europe	Sell	1,700	$22.29	$38K
Nov 18, 2025	Lanoy Jonathan DavidSVP, Chief Accounting Officer	Sell	5,000	$20.45	$102K
Nov 14, 2025	Brower Nathan GEVP, General Counsel	Sell	3,800	$20.81	$79K
Nov 12, 2025	Norman Daniel CEVP & President, Asia	Sell	8,884	$20.46	$182K

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

What Changed

Risk factors · Mar 11, 2025 → Mar 10, 2026

18 added · 15 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.

Newly disclosed

In addition, in April 2025 we filed an initial voluntary self-disclosure with the Office of Foreign Asset Control (“OFAC”) relating to the same internal investigation.
Following our internal investigation, we filed final voluntary self-disclosures with BIS and OFAC on September 5, 2025.
On December 17, 2025, we completed these purchases, acquiring the interest in Nature’s Sunshine Hong Kong Limited for $3.1 million and the interest in Shanghai Nature’s Sunshine Health Products for total consideration consisting of $2.9 million paid at closing and an additional $1.0 million payable on December 17, 2027.
(iii) risks related to our ability to satisfy the deferred purchase price obligation due December 17, 2027; and (iv) broader China-related risks, including changes in PRC laws or regulations, foreign exchange controls, restrictions on the repatriation of funds, and potential adverse treatment by Chinese or other authorities.
(“Fosun Industrial,” an affiliate of Fosun Pharma) to purchase Fosun Industrial’s interests in our two joint ventures, Nature’s Sunshine Hong Kong Limited and Shanghai Nature’s Sunshine Health Products Co., Ltd., for cash consideration of $3.9 million and $3.1 million, respectively.
Similar incidents could occur in the future and could result in additional losses, regulatory inquiries, litigation or reputational harm.
As the primary manufacturer of our own products, we are subject to FDA regulations on Good Manufacturing Practices (“GMP”), which require us to maintain good manufacturing processes, including ingredient identification, manufacturing controls and record keeping.
In the future, we may be subject to additional laws or regulations administered by the FDA or other federal, state, local or foreign regulatory authorities, the repeal or amendment of laws or regulations which we consider favorable and/or more stringent interpretations of current laws or regulations.
Improper or unsubstantiated product or earnings claims by independent consultants, even where contrary to our policies, may subject us to regulatory investigations, enforcement actions, fines, penalties, product relabeling requirements or reputational harm.
If regulators determine that we are responsible for such violations, we could be subjected to investigations, enforcement actions, significant financial penalties, costly mandatory product recalls or relabeling requirements, any of which could have a material adverse effect on our results of operations and financial condition.
We may need to adjust our operating procedures in response to these interpretational changes, and such changes could have a material adverse effect on our results of operations and financial condition. 16 Table of Contents If we fail to maintain an effective system of internal controls, we may not be able to report our financial results accurately, may make a material misstatement in our financial statements, or may experience a financial loss.
As a result of these transactions, we now face risks inherent in directly owning and operating these businesses in China (including Hong Kong), including: (i) integration risks as we transition to direct ownership;

No longer disclosed

If our remediation measures are insufficient to address the material weaknesses, or if additional material weaknesses or significant deficiencies in our internal control are discovered or occur in the future, our financial statements may contain material misstatements, we could experience another financial loss or we could be required to restate our financial results, which could lead to substantial additional costs for accounting and legal fees and stockholder litigation.
As the primary manufacturer of our own products, we are subject to FDA regulations on Good Manufacturing Practices (“GMP”), which require us to maintain good manufacturing processes, including ingredient identification, manufacturing controls and record keeping. 11 Table of Contents In the future, we may be subject to additional laws or regulations administered by the FDA or other federal, state, local or foreign regulatory authorities, the repeal or amendment of laws or regulations which we consider favorable and/or more stringent interpretations of current laws or regulations.
If our independent consultants fail to comply with these restrictions, then we could be subjected to claims of false advertising, misrepresentation, significant financial penalties, costly mandatory product recalls and relabeling requirements, any of which could have a material adverse effect on our results of operations and financial condition.
A widespread pandemic and measures taken in response by governments and businesses worldwide to contain its spread, including quarantines, facility closures, travel and logistics restrictions, border controls and shelter in place or stay at home and social distancing orders, may adversely impact our supply chain, manufacturing, logistics, workforce and operations, as well as the operations of our customers and suppliers globally.
We continue to evaluate, design and work through the process of implementing controls and procedures under a remediation plan designed to address this material weakness, but there can be no assurance that we will be able to remediate this material weakness in a timely manner or at all.
Any disruption in relations, inability to work efficiently or disadvantageous treatment of the joint venture by the Chinese or other authorities could have a material adverse effect on our results of operations and financial condition.
If we fail to maintain an effective system of internal controls, we may not be able to report our financial results accurately, may make a material misstatement in our financial statements, or may experience a financial loss.
Such adverse impacts on our supply chain could limit our ability to manufacture and sell our products on a timely and cost-effective basis, which could adversely affect our business and results of operations.
Effective operation of the joint venture depends on good relations between us and Fosun Pharma, active synergies between the two companies and positive legal and regulatory recognition of the joint venture.
If we are required to make changes, or if the FTC seeks to enforce similar measures in the industry, either through rulemaking or an enforcement action against our company, our business could be harmed.
We may need to adjust our operating procedures in response to these interpretational changes, and such changes could have a material adverse effect on our results of operations and financial condition.
These and other attacks could result in additional losses and harm our business and results of operations.

Similar companies

Comparable business profile · signals at a glance

HLFHERBALIFE LTD.$1.3B+2.0%NUSNU SKIN ENTERPRISES, INC.$265.6M-0.2%NGVCNatural Grocers by Vitamin Cottage, Inc.$727.6M-2.0%USNAUSANA HEALTH SCIENCES INC$367.6M+1.5%LCUTLIFETIME BRANDS, INC$203.2M+17.9%PBHPrestige Consumer Healthcare Inc.$2.3B-2.8%